At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 27 enrolled
Drug / intervention
Human Amniotic Membranebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Feasibility Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation After Coronary Artery Bypass Grafting
In Brief
A Early Phase 1 clinical trial evaluating Human Amniotic Membrane for Atrial Fibrillation. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Timeline
Early Ph 1CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedOct 2019
Primary CompletionJun 2021
TodayJul 2026
First PostedOct 17, 2019
Enrollment StartOct 11, 2019
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.7 years ago
Interventions
Human Amniotic Membranebiological
Epicardial application of human amniotic membrane during cardiac surgery